Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?

At present, SARS-CoV-2 vaccines have shown excellent efficacy to prevent COVID-19 but immunocompromised patients were left-off most vaccine clinical trials albeit their extreme vulnerability [[1]]. Several studies showed that patients with HM, particularly lymphoid malignancies, had a lower antibody response to COVID-19 vaccines than general population and might be left unprotected from SARS-CoV-2 infection [[3], [5]]. Keywords: COVID-19; SARS-CoV-2; vaccine; cellular immunity; hematologic malignancies EN COVID-19 SARS-CoV-2 vaccine cellular immunity hematologic malignancies 743 746 4 03/07/22 20220301 NES 220301 SARS-CoV-2 vaccines offered great hope in controlling the worldwide COVID-19 pandemic. At initiation of vaccination against COVID-19, 10 patients were receiving ibrutinib, 5 patients were receiving anti-CD20 treatments (4 rituximab and 1 obinutuzumab), including 3 patients receiving a combination of ibrutinib and rituximab. [Extracted from the article]